Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight (Funded by Innovent Biologics; GLORY-1 ClinicalTrials gov number, NCT05607680 )
Mazdutide in Chinese Adults with Obesity or Overweight Obesity and overweight are well-recognized risk factors for a range of diseases New research evaluating the efficacy and safety of mazdutide in long-term weight management is summarized in a
Once Weekly Mazdutide effectvely reduced body weight in obese . . . A new study published in The New England Journal of Medicine showed that once weekly mazdutide at a dosage of 4 mg or 6 mg for 32 weeks resulted in clinically significant weight loss in Chinese adults who were overweight or obese
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight (Funded by Innovent Biologics; GLORY-1 ClinicalTrials gov number, NCT05607680 )
中国原创减重药，效果媲美减肥神药司美格鲁肽！北大学者发文NEJM - 知乎 题为：“Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight”。 该试验比较了中国肥胖或超重成人每周一次注射 玛仕度肽 和安慰剂的疗效。结果显示，在中国超重或肥胖成人患者中，每周一次注射4 mg或6 mg玛仕度肽并持续32周，可使体重发生有临床意义的减轻。
A phase 2 randomised controlled trial of mazdutide in Chinese . . . Overweight adults (body-mass index [BMI] ≥24 kg m 2) accompanied by hyperphagia and or at least one obesity-related comorbidity or adults with obesity (BMI ≥ 28 kg m 2) were randomly assigned (3:1:3:1:3:1) to once-weekly mazdutide 3 mg, 4 5 mg, 6 mg or matching placebo at 20 hospitals in China